^
Association details:
| Biomarker: | DNMT3A mutation |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | sepantronium bromide (PC-002) (Survivin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3942 DNMT3A Mutations Enhance T-ALL Survival, Which Is Reversed By JAK/STAT Inhibition
Published date:
11/03/2022
Excerpt:
Following treatment with the BIRC5 inhibitor YM155, the viability of DNMT3A-mutant T-ALL cells decrease significantly compared to DNMT3A-wildtype PDXs, which were relatively unaffected….These data provide a critical first step towards a novel target for precision medicine approaches for this patient group.
DOI:
https://doi.org/10.1182/blood-2022-167136
